Stocktoria
Roivant Sciences Ltd. ROIV
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2020-12-03
Roivant Sciences Ltd. statistics & valuation
Market cap$24.5B
P / B4.6×
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Operating margin | -6235.7% | -3453.3% | 13746.9% | -2875.9% | -2444.8% |
| Net margin | -3629.2% | -592.0% | 13294.2% | -3200.2% | -1528.9% |
| FCF margin | -9183.5% | -2905.2% | -2343.6% | -2715.1% | -1257.4% |
| Return on assets | -5.3% | -3.2% | 60.2% | -42.2% | -32.7% |
| Return on equity | -5.7% | -3.3% | 67.4% | -62.8% | -41.5% |
| Debt / equity | — | — | 0.07× | 0.23× | 0.10× |
| Current ratio | 18.37 | 33.47 | 25.24 | 6.60 | 11.64 |
| Revenue growth | -71.6% | -11.2% | 3.8% | -43.0% | 132.3% |
Source: SEC EDGAR filings · CIK 0001635088 · as of 2026-03-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.